Furthermore, we determined that overexpression of TACC3 promotes G1/S transition via the transcriptional activation of E2F1. Importantly, cancer cells that express high levels of TACC3 or E2F1 display increased sensitivity to cisplatin. The gene discussed is TACC3; the disease is cancer.